{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:08:40Z","timestamp":1792174120618,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Glenmark Pharmaceuticals Limited"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijid.2020.10.069","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T23:43:16Z","timestamp":1604101396000},"page":"501-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":373,"special_numbering":"C","title":["Role of favipiravir in the treatment of COVID-19"],"prefix":"10.1016","volume":"102","author":[{"given":"Shashank","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalil","family":"Parkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-3188","authenticated-orcid":false,"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2020.10.069_bib0005","unstructured":"Avigan Tablet 200 mg. Deliberation Results by PMDA (2014). https:\/\/www.pmda.go.jp\/files\/000210319.pdf\/ 2020 (accessed on 3 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0010","unstructured":"Favipiravir, a broad-spectrum antiviral and potential therapeutic for COVID-19. http:\/\/www.tibdn.ca\/control-covid\/files\/protocol\/at_download\/file\/ 2020 (accessed on 27 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0015","unstructured":"Protocol COVID-FPR-01, July 7. 2020. https:\/\/clinline.ru\/reestr-klinicheskih-issledovanij\/180-23.04.2020.html. (accessed on 7 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0020","unstructured":"Russia\u2019s ChemRar reports positive data of Favipiravir in Covid-19. https:\/\/www.clinicaltrialsarena.com\/news\/chemrar-rdif-favipiravir-data\/ 2020 (accessed on 4 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0025","unstructured":"Saudi MoH protocol for patients suspected of\/confirmed with covid-19 supportive care and antiviral treatment of suspected or confirmed COVID-19 infection (version 1.8). https:\/\/www.moh.gov.sa\/Ministry\/MediaCenter\/Publications\/Documents\/MOH-therapeutic-protocol-for-COVID-19.pdf\/ 2020 (accessed on 7 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0030","unstructured":"The drug was approved for the treatment of COVID-19 in the hospital settings in Russia on May 29, 2020, after an ongoing open-label randomized clinical trial had recruited 60 subjects on favipiravir. https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/russian-drug-to-treat-covid-to-be-delivered-to-hospitals-in-june\/articleshow\/76131135.cms\/2020 (accessed on 22 August 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","author":"Arshad","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2020.10.069_bib0040","unstructured":"Auwaerter PG. Coronavirus COVID-19 (SARS-CoV-2), July 3. 2020. https:\/\/nam03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.hopkinsguides.com%2Fhopkins%2Fview%2FJohns_Hopkins_ABX_Guide%2F540747%2Fall%2FCoronavirus_COVID_19__SARS_CoV_2_&data=04%7C01%7CZ.french%40elsevier.com%7Cb03f57a6430f4d4c99ce08d8936b3608%7C9274ee3f94254109a27f9fb15c10675d%7C0%7C0%7C637421435975715693%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=RYV7NlCXQkz%2BLO%2B9qBEyBsL1gxmlAm4ltVkZ9pEO2rQ%3D&reserved=0 (accessed on 3 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (t-705)-sierra leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2020.10.069_bib0050","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"issue":"May","key":"10.1016\/j.ijid.2020.10.069_bib0055","article-title":"Severe Covid-19","author":"Berlin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0060","article-title":"Experimental treatment with favipiravir for covid-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.ijid.2020.10.069_bib0065","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0070","doi-asserted-by":"crossref","first-page":"e2790","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2020.10.069_bib0075","series-title":"Coronavirus disease 2019 (COVID-19) clinical care","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"10.1016\/j.ijid.2020.10.069_bib0080","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijid.2020.10.069_bib0085","unstructured":"Clinical trial registry-India. https:\/\/nam03.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fwww.ctri.nic.in%2FClinicaltrials%2Fpdf_&data=04%7C01%7CZ.french%40elsevier.com%7Cb03f57a6430f4d4c99ce08d8936b3608%7C9274ee3f94254109a27f9fb15c10675d%7C0%7C0%7C637421435975715693%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=lDUTAkPeWFQTjcEzJDoHvEvdH1HdgeVQIDdBbeSMDz4%3D&reserved=0 generate. php?trialid=43504&EncHid=&modid=&compid=%27,%2743504det%27\/2020 (accessed on 22 August 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir Res"},{"issue":"September","key":"10.1016\/j.ijid.2020.10.069_bib0095","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19","author":"Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2020.10.069_bib0100","series-title":"Preliminary report of the favipiravir observational study in Japan (2020\/5\/15)","author":"Doi","year":"2020"},{"key":"10.1016\/j.ijid.2020.10.069_bib0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.ijid.2020.10.069_bib0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2020.10.069_bib0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpt.1878","article-title":"Response to \u201cdose rationale for favipiravir use in patients infected with SARS-CoV-2\u201d","volume":"108","author":"Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2020.10.069_bib0120","first-page":"198","article-title":"Update on treatment of COVID-19: ongoing studies between promising and disappointing results","volume":"28","author":"Esposito","year":"2020","journal-title":"Infez Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0125","series-title":"Fabiflu prescribing information","year":"2020"},{"key":"10.1016\/j.ijid.2020.10.069_bib0130","unstructured":"Favipiravir - FUJIFILM Toyama Chemical. https:\/\/adisinsight. springer. com\/ drugs\/800014667\/ 2020 (accessed on 3 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.ijid.2020.10.069_bib0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrumbroad-spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.ijid.2020.10.069_bib0145","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2020.10.069_bib0150","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response","volume":"5","author":"Goyal","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijid.2020.10.069_bib0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijid.2020.10.069_bib0160","unstructured":"JapicCTI-205238. 2020. https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=JapicCTI-205238\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2020.10.069_bib0170","unstructured":"jRCTs031190226. 2020. https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=jRCTs031190226\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0175","unstructured":"jRCTs041190120. 2020. https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCTs041190120\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2020.10.069_bib0185","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2020.10.069_bib0190","first-page":"ciaa851","article-title":"Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019","author":"Magleby","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2020.10.069_bib0195","unstructured":"Ministry of Health of Russia and Rospotrebnadzor. Temporary methodological recommendations prevention, diagnostics and treatment of a new coronavirus infections (Covid-19). Version 7 (06\/03\/2020). https:\/\/nam03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fstatic-0.rosminzdrav.ru%2F&data=04%7C01%7CZ.french%40elsevier.com%7Cb03f57a6430f4d4c99ce08d8936b3608%7C9274ee3f94254109a27f9fb15c10675d%7C0%7C0%7C637421435975715693%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=X%2FAvFyMg9lX3AfUe5gHX%2BJLRWJK4FuV5kDaJzBRdHWU%3D&reserved=0 system\/attachments\/attaches\/000\/050\/584\/original\/03062020_%D0%9CR_COVID-19_v7.pdf\/ 2020 (accessed on 7 July 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0200","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","article-title":"Use of antiviral drugs to reduce COVID-19 transmission","volume":"8","author":"Mitj\u00e0","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijid.2020.10.069_bib0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.ijid.2020.10.069_bib0210","unstructured":"National Center for Biotechnology Information. PubChem Database. Favipiravir, CID=492405. https:\/\/nam03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fcompound%2FFavipiravir%2F&data=04%7C01%7CZ.french%40elsevier.com%7Cb03f57a6430f4d4c99ce08d8936b3608%7C9274ee3f94254109a27f9fb15c10675d%7C0%7C0%7C637421435975715693%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=RlTSEi%2BaRWSYvUYenUbOU119s9ySQNTS29n1uMEf5Gw%3D&reserved=0 2020 (accessed on 11 June 2020)."},{"key":"10.1016\/j.ijid.2020.10.069_bib0215","unstructured":"NCT 04310228. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04310228\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0220","unstructured":"NCT04303299. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303299\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0225","unstructured":"NCT04319900. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04319900\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0230","unstructured":"NCT04333589. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333589\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0235","unstructured":"NCT04336904. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336904\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0240","unstructured":"NCT04345419. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345419\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0245","unstructured":"NCT04346628. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346628\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0250","unstructured":"NCT04349241. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04349241\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0255","unstructured":"NCT04351295. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04351295\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0260","unstructured":"NCT04356495. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04356495\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0265","unstructured":"NCT04358549. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358549\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0270","unstructured":"NCT04359615. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359615\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0275","unstructured":"NCT04373733. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04373733\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0280","unstructured":"NCT04448119. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04448119\/. [Accessed on 24 July 2020]."},{"key":"10.1016\/j.ijid.2020.10.069_bib0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0091270003260336","article-title":"Human liver aldehyde oxidase: inhibition by 239 drugs","volume":"44","author":"Obach","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2020.10.069_bib0290","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJMe2001126","article-title":"Another decade, another coronavirus","volume":"382","author":"Perlman","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0295","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir \u2014 a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.ijid.2020.10.069_bib0300","article-title":"Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multicenter observational study","author":"Rattanaumpawan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijid.2020.10.069_bib0305","series-title":"Standard treatment protocol for COVID-19 positive patients (Revision 2: 22-06-2020) \u2014 Corona-2020\/CR No.58\/Aa-5\/2020","year":"2020"},{"key":"10.1016\/j.ijid.2020.10.069_bib0310","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/ph13050096","article-title":"The rationale for potential pharmacotherapy of COVID-191","volume":"13","author":"Saber-Ayad","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijid.2020.10.069_bib0315","article-title":"Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase","author":"Shannon","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijid.2020.10.069_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijid.2020.10.069_bib0325","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0330","series-title":"Guidance of antiviral drug treatment for COVID-19","author":"The Japanese Association for Infectious Diseases","year":"2020"},{"key":"10.1016\/j.ijid.2020.10.069_bib0335","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-020-01636-4","article-title":"A prospect on the use of antiviral drugs to control local outbreaks of COVID-19","volume":"18","author":"Torneri","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ijid.2020.10.069_bib0345","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2020.10.069_bib0350","doi-asserted-by":"crossref","first-page":"102916","DOI":"10.1016\/j.ebiom.2020.102916","article-title":"Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis","volume":"58","author":"Weiss","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2020.10.069_bib0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/joim.13063","article-title":"Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)","volume":"288","author":"Wu","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijid.2020.10.069_bib0360","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.cub.2020.03.063","article-title":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr Biol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220322736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220322736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:58:57Z","timestamp":1761119937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220322736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":72,"alternative-id":["S1201971220322736"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.10.069","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of favipiravir in the treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.10.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}